**Table 2. Rare *PRKN* heterozygous SNV and CNV analysis for risk of Parkinson’s disease using SKAT-O adjusted for age, sex, ethnicity and *GBA* and *LRRK2* status.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Carriers in patients, No. (%) | Carriers in controls, No. (%) | *P-*valuea |
| McGill University (n = 2964) |
| SNV | 91 (12.2) | 230 (10.4) | 0.594 |
| CNV | 4 (0.537) | 15 (0.676) | 0.608 |
| SNV & CNV | 93 (12.5) | 238 (10.7) | 0.621 |
| Patho SNV | 11 (1.48) | 22 (0.991) | 0.675 |
| Patho SNV & CNV | 15 (2.01) | 37 (1.67) | 0.675 |
| No Benign SNV | 67 (8.99) | 152 (6.85) | 0.507 |
| No Benign SNV & CNV | 69 (9.26) | 160 (7.21) | 0.552 |
| Columbia University (n = 1,420) |
| SNV | 101 (10.9) | 45 (9.16) | 0.614 |
| CNV | 13 (1.4) | 11 (2.24) | 0.507 |
| SNV & CNV | 109 (11.7) | 52 (10.6) | 0.588 |
| Patho SNV | 5 (0.538) | 5 (1.02) | 0.507 |
| Patho SNV & CNV | 18 (1.94) | 16 (3.26) | 0.502 |
| No Benign SNV | 76 (8.18) | 31 (6.31) | 0.507 |
| No Benign SNV & CNV | 85 (9.15) | 38 (7.74) | 0.507 |
| Sheba Medical Center (n = 1,139) |
| SNV | 45 (7.12) | 25 (4.93) | 0.507 |
| CNV | 2 (0.316) | 4 (0.789) | 0.584 |
| SNV & CNV | 46 (7.28) | 27 (5.33) | 0.507 |
| Patho SNV | 0 (0) | 1 (0.197) | 0.679 |
| Patho SNV & CNV | 2 (0.316) | 5 (0.986) | 0.584 |
| No Benign SNV | 42 (6.65) | 23 (4.54) | 0.502 |
| No Benign SNV & CNV | 43 (6.8) | 25 (4.93) | 0.507 |
| Meta-Analysis (n = 5,523) |
| SNV | 237 (10.3) | 300 (9.35) | 0.507 |
| CNV | 19 (0.824) | 30 (0.933) | 0.507 |
| SNV & CNV | 248 (10.7) | 317 (9.84) | 0.507 |
| Patho SNV | 16 (0.695) | 28 (0.87) | 0.646 |
| Patho SNV & CNV | 35 (1.52) | 58 (1.8) | 0.553 |
| No Benign SNV | 185 (8.02) | 206 (6.4) | 0.461 |
| No Benign SNV & CNV | 197 (8.54) | 223 (6.93) | 0.461 |

Abbreviations: SNV―Single Nucleotide Variant; CNV―Copy Number Variation; Patho―pathogenic and likely pathogenic variants; No Benign―analysis excluding benign and likely benign variants.

a P-values shown are after FDR correction (q value <= 0.05).